Agios to Present New Clinical Data from its IDH Programs at ASCO
– Updated Data from IDHIFA® (Enasidenib) Phase 1 Trial in IDH2m R/R AML to be Presented in Oral Presentation; Abstract Selected for Best of ASCO Program –
–
In total, three abstracts led by Agios describing new data from the company's IDH programs have been accepted for presentation at
The accepted abstracts are listed below and are available online on the
Oral presentation by Agios and
Title: Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase 1 dose-escalation and expansion study
Date & Time:
Oral Abstract Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: 7004
Location: E450ab
Presenter:
This abstract has been selected as part of the “Best of ASCO” program to be presented in cities across the country. “Best of ASCO” features the top abstracts, highlighting the most cutting-edge science and education from the annual meeting.
Poster discussions and poster presentations by Agios and/or
Title: Phase 1 study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts
Poster Session Date & Time:
Poster Discussion Date & Time:
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Abstract: 4015
Poster Board: 7
Poster Location: Hall A
Poster Discussion Location: Hall D2
Presenter:
Title: Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2)
Poster Session Date & Time:
Poster Discussion Date & Time:
Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: 7015
Poster Board: 215
Poster Location: Hall A
Poster Discussion Location: E354b
Presenter: Amir Tahmasb Fathi, M.D.,
Title: Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors
Date & Time:
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Abstract: 4082
Poster Board: 74
Location: Hall A
Author: Bin Fan, Ph.D.,
Title: ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation
Date & Time:
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Abstract: TPS4142
Poster Board: 128b
Location: Hall A
Author:
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
About Agios/Celgene Collaboration
IDHIFA® (enasidenib) and AG-881 are part of Agios' global strategic collaboration with
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Agios’ plans, strategies and expectations for its and its collaborator’s preclinical, clinical and commercial advancement of its drug development programs including IDHIFA® (enasidenib) and ivosidenib (AG-120); the potential benefits of Agios' product candidates; its plans regarding future data presentations; and the potential benefit of its strategic plans and focus. The words “intend,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios or its collaborator,
Contacts Investors:Kendra Adams , 617-844-6407 Senior Director, Investor & Public Relations Kendra.Adams@agios.comRenee Leck , 617-649-8299 Senior Manager, Investor & Public Relations Renee.Leck@agios.com Media:Holly Manning , 617-844-6630 Associate Director, Corporate Communications Holly.Manning@agios.com